MHRA Approves Vimseltinib for Giant Cell Tumours

The MHRA on 14 August 2026 approved vimseltinib, sold as Romvimza, for adults with tenosynovial giant cell tumour (TGCT) whose disease affects their movement or who cannot undergo surgery. It is a UK-specific decision, arriving roughly a year and a half after the drug's first approval in the United States and nearly a year after the European Commission cleared it for the EU — a reminder that a UK marketing authorisation is its own regulatory event, on its own clock, even for a drug already established elsewhere.

What the approval covers

The authorised population is narrow and deliberately defined: adults with TGCT whose symptoms affect movement, or for whom surgery — the standard first-line treatment for TGCT — is not an option, whether because of the tumour's location, its diffuse growth pattern, or a patient's overall fitness for an operation. TGCT typically develops around a single joint, most commonly the knee or ankle, in young and middle-aged adults, and can progress to persistent pain, swelling, stiffness, and a shrinking range of motion. Vimseltinib works by blocking the colony-stimulating factor 1 receptor (CSF1R), a target implicated in the abnormal cell proliferation that drives the tumour's growth.

Dosing and the monitoring condition

Vimseltinib is dosed as an oral capsule, swallowed whole, taken twice a week with or without food — a comparatively light regimen against a chronic condition. MHRA has placed the drug under additional monitoring, the status it applies to newer medicines where the agency wants a closer post-approval safety picture; the most commonly reported effects associated with the drug include fatigue, periorbital and peripheral swelling, itching, rash, elevated blood pressure, and changes in liver enzymes, cholesterol, creatinine, and neutrophil counts. Patients and clinicians are directed to the Yellow Card scheme, the UK's mechanism for reporting suspected adverse reactions, to feed that monitoring.

A UK decision on its own track

Vimseltinib's regulatory history runs through Washington and Brussels before it reaches London. The FDA granted full approval in the US in February 2025; the European Commission followed with an EU-wide approval in September 2025, after a positive opinion from the EMA's human medicines committee. The MHRA's authorisation this week does not depend procedurally on either of those decisions — the UK has run its own marketing authorisation process since exiting the EU's centralised system — but it does follow a broadly similar evidentiary record. What comes next in the UK is a separate access question: the National Institute for Health and Care Excellence is running its own appraisal of vimseltinib for TGCT, tracked under project ID GID-TA11640, which will determine whether and how the NHS funds it. A marketing authorisation makes a drug legal to prescribe; a NICE recommendation is what usually makes it routinely available on the NHS.